

MiRXES unveils APAC's first T10 ultra-high throughput sequencing platform

22 November 2022 | News

The T10 sequencing platform will provide a significant boost to Singapore's sequencing power and build a highresolution spatial transcriptomics pipeline in Singapore

MiRXES, a Singapore-headquartered biotechnology company, has unveiled the cutting-edge DNBSEQ-T10×4RS Genetic Sequencing System (T10), the world's largest and highest throughput next generation sequencer. In the presence of Dr Wang Jian, Chairman and Co-founder of BGI Group, the platform was launched.

The T10 sequencing platform, housed at MiRXES's purpose-built multi-omics laboratory at Singapore's Biopolis, is the first of its kind installed and operationalised in the Asia-Pacific (APAC) Region, outside of China, made possible via a strategic partnership between MiRXES, MGI, and BGI-Research.

Through this new platform, MiRXES plans to partner local research and healthcare institutions as well as pharmaceutical and biotech companies to scale the positive impact of genomics for Singapore and the region.

The T10 sequencing platform will provide a significant boost to Singapore's sequencing power and enable ultra-high throughput multi-omics research including a transformational, high-resolution spatial-temporal transcriptomics pipeline powered by BGI-Research's Stereo-seq technology.

Dr Lihan ZHOU, Co-founder and CEO for MiRXES, said, "The T10 sequencing platform, a key enabler to discover new biology and identify novel biomarkers for early detection of diseases and precision medicine, will help to develop and scale up preventive health solutions in Singapore and the region."